The Zhitong Finance App learned that Datroway, an antibody-conjugated drug (ADC) jointly developed by AstraZeneca (AZN.US) and its partner Daiichi Sankyo, has been approved by the US Food and Drug Administration (FDA) to treat adult patients with locally advanced or metastatic EGFR mutation non-small cell lung cancer (NSCLC) who have previously received EGFR targeted therapy and platinum chemotherapy. This approval provides new treatment options for patients with EGFR mutant NSCLC after multi-line treatment. AstraZeneca added that this is the first drug approved in the US to treat this type of lung cancer.

The Zhitong Finance App learned that Datroway, an antibody-conjugated drug (ADC) jointly developed by AstraZeneca (AZN.US) and its partner Daiichi Sankyo, has been approved by the US Food and Drug Administration (FDA) to treat adult patients with locally advanced or metastatic EGFR mutation non-small cell lung cancer (NSCLC) who have previously received EGFR targeted therapy and platinum chemotherapy. This approval provides new treatment options for patients with EGFR mutant NSCLC after multi-line treatment. AstraZeneca added that this is the first drug approved in the US to treat this type of lung cancer.